fda semaglutide warning september 2025 alerts - Fda warningletters retatrutide FDA warns consumers not to use counterfeit Ozempic (semaglutide FDA Semaglutide Warning September 2025: Navigating Regulatory Actions and Drug Safety

RetatrutideFDAStatus The FDA has been actively issuing a series of warning letters throughout September 2025, targeting companies involved in the marketing and distribution of semaglutide and related drugs, particularly those compounded or marketed for weight loss.Lilly, Novo, Hims Get FDA Warnings About Misleading ... These actions underscore the FDA's commitment to patient safety and ensuring that medications meet stringent regulatory standards. This proactive enforcement is crucial for consumers seeking effective and safe treatment options.

A significant development in September 2025 was the FDA's issuance of over 50 warning letters to telehealth-based companies. These letters specifically address the unsubstantiated claims and misleading advertising surrounding GLP-1 and compounded semaglutide products.FDA Drug Recalls and Warnings: Illegal GLP-1 Sales and ... The agency emphasized that products like Ozempic (containing semaglutide) and Wegovy carry inherent risks that must be clearly communicated to consumersFDA Drug Recalls and Warnings: Illegal GLP-1 Sales and .... The FDA warns consumers not to use counterfeit Ozempic (semaglutide) found in the U.Published Date: 12/03/2025. Type: DWPE. ImportAlertName: Detention Without Physical Examination of Glucagon-Like ... 61P[][]72Semaglutide(Anti-Diabetic)S. drug supply chain, highlighting recent seizures of such products on December 5, 2025.

Furthermore, September 9, 2025, marked a critical date for several entities.Semaglutide Safety Alerts, Recalls & Warnings GLP-1 Solution and JulyMD received WARNING LETTER. September 9, 2025, indicating that their compounded semaglutide products were deemed misbranded drugs under FDCA sections 502(a) and 502(bb). Novo Nordisk Inc4天前—In July 2023, after receiving post-marketing reports of SI/B in patients taking GLP-1RA medications, theFDAinitiated an investigation into .... also received a warning letter on the same date, concerning the boxed warning on Ozempic regarding the risk of thyroid C-cell tumors.2025年10月7日—OnSeptember 9, 2025, the agency significantly increased its enforcement activity by issuing more than 40warningletters to telehealth-based ... This warning is critical for understanding the potential side effects associated with semaglutide. The FDA also issued warning letters to manufacturers of Ozempic, Wegovy, Victoza, Mounjaro, and Zepbound on September 9, 2025, regarding promotional claims[2/21/2025]FDAhas determined the shortage ofsemaglutideinjection products, a glucagon-like peptide 1 (GLP-1) medication, is resolved.Semaglutide....

In an effort to bolster the integrity of the drug supply chain, the FDA established a "green list" import alert on September 5, 2025. This initiative, identified as Import Alert 66-80 with a published date of December 3, 2025, aims to prevent the entry of GLP-1 Active Pharmaceutical Ingredients (APIs) with potential quality concerns into the U.S. market.Beyond the Headlines: FDA Warning Letters to GLP-1 ... This move is particularly relevant for semaglutide and other GLP-1 medications, ensuring that only vetted and safe sources contribute to the drug supply.

The crackdown extends to direct-to-consumer advertising as well. On September 16, 2025, the FDA published more than 55 warning letters as the agency significantly increased its enforcement activity.FDA warns consumers not to use counterfeit Ozempic ... These letters, nearly identical in nature, asserted that the marketing of compounded semaglutide by certain companies was illegal. Recipients of these warnings were advised to cease such practices immediately.PLAINSBORO, NJ, December 5,2025-FDArecently seized dozens of units of counterfeit Ozempic (semaglutide) injection 1 mg distributed illegally outside of Novo ... Similar actions were taken on September 15, 2025, when the FDA warned telehealth company Hims & Hers to stop using misleading language in their promotions.

The FDA's concerns are not limited to compounded versions. On September 25, 2025, the agency highlighted awareness of fraudulent compounded semaglutide and tirzepatide marketed with false product label informationManagealertsfor this article · Email this article; Share this article. Glass vials Adobe. By Katie Palmer.Sept. 19, 2025. Health Tech Correspondent.. This vigilance aims to protect patients from unapproved and potentially dangerous drugs. The FDA has also been investigating reports of suicidal ideation and behavior associated with GLP-1RA medications, including liraglutide (Saxenda) and semaglutide (Wegovy), since July 2023, with updates provided on January 13, 2026. Several articles from September 2025 discuss the FDA's stance on GLP-1 drug marketing, with specific attention to Sept.2025年12月5日—FDA warns consumers not to use counterfeit Ozempic (semaglutide) found in U.S. drug supply chain. [12/5/2025] FDA recently seized dozens of ... 19, 2025, when FDA warned telehealth providers about obesity drug marketing.

It is important to note that as of February 2025, the FDA announced the resolution of the shortage for semaglutide injection products.JulyMD September 09, 2025 This has significant implications for patients, as it means standard 503A and 503B pharmacy rules now apply, and compounded semaglutide/tirzepatide products were set to phase out by late May 2025, encouraging a switch to FDA-approved alternativesFDA puts compounded weight loss drug advertising in its ....

The FDA's comprehensive actions throughout September 2025 reflect a concerted effort to safeguard public health by addressing issues related to drug safety, efficacy, and marketing. Consumers seeking semaglutide or other GLP-1 medications should prioritize FDA-approved products and be wary of unverified sources or exaggerated claims, particularly when dealing with telehealth providers. The agency's ongoing scrutiny, including past warnings and investigations, highlights the critical importance of adhering to regulatory guidelines in the pharmaceutical landscape2025年9月8日—OnSeptember5, the U.S. Food and Drug Administration (FDA) launched a green list importalertthat identifies safe sources of active GLP-1 ....